Go premium today and get access to all the details and pitch decks

GenLumina

Direct Message
Website
Download Pitch Deck
Export data
August 6, 2025
Data is self reported

GenLumina

We eliminate cancer cell by cell with a new drug that is only activated with light.

Achievement

For this startup there is an actual piece of text here instead of this blurred text. It's available to active investors and investors on a paid plan.

Founded in

2024

Country

Netherlands

Province

Some blurred text here

Industry

BioTech

SDGs

For this startup there is an actual piece of text here instead of this blurred text. It's available to active investors and investors on a paid plan.

Patent information

For this startup there is an actual piece of text here instead of this blurred text. It's available to active investors and investors on a paid plan.

Team

Number of founders

Some blurred text here

Number of employees

Founder backgrounds

Exit experience

Some blurred text here

Relevant industry experience

Some blurred text here

Previous startup experience

Some blurred text here

Female founder

Some blurred text here

EUR / Erasmus MC or TUDelft relation

Some blurred text here

Graduation year from EUR, Erasmus MC or TUDelft

Some blurred text here

In the news

Investment details

Amount raising

500000

Ownership founders

Some blurred text here

Lead investor

Some blurred text here

Current investors

Some blurred text here

Intended closing date

Some blurred text here

Fundraising status

Some blurred text here

Already committed

Some blurred text here

Revenue Metrics

Monthly revenue

Some blurred text here

Monthly growth

Some blurred text here

Paying customers

Some blurred text here

Monthly active users

Some blurred text here

GenLumina

Direct Message
Website
Download Pitch Deck
Share
Export data
August 6, 2025
Data is self reported

GenLumina

We eliminate cancer cell by cell with a new drug that is only activated with light.

Achievement

Raised 1 million on research money in half a year. Grant for collaboration research with LUMC-hospital with their targeting peptide for colorectal cancer and our drug as payload. Six testimonials from Key Opinion Leaders stating our drug is clinical relevant for brainsurgery, dermatology, radiology and image guided surgery. Our proposition was rated 7,5 on the Bio Expert Network by 14 experts and selected for a campaign on a crowdfunding platform.

Founded in

2024

Country

Netherlands

Province

Zuid-Holland

Industry

BioTech

SDGs

Good health and well-being (SDG #3)

Patent information

For our new drug, we have an exclusive licence agreement worldwide with University of Leiden

Team

Number of founders

3

Number of employees

Founder backgrounds

Exit experience

No

Relevant industry experience

No

Previous startup experience

Yes

Female founder

No

EUR / Erasmus MC or TUDelft relation

Graduation year from EUR, Erasmus MC or TUDelft

In the news

Investment details

Amount raising

500000

Ownership founders

80-99% owned by founders

Lead investor

no

Current investors

1000000

Intended closing date

Q3 this year

Fundraising status

Actively fundraising (brand name visible)

Already committed

500000

Revenue Metrics

Monthly revenue

pre-revenue

Monthly growth

not growing

Paying customers

0

Monthly active users

0

GenLumina

saving...
We eliminate cancer cell by cell with a new drug that is only activated with light.
Direct MessageSend Message

Premium Details Available

(Data is self reported)

FINANCIAL PERFORMANCE

Monthly Revenue
blurred values
Growth rate month over month
blurred values
Monthly revenue context
blurred values
Number of paying customers
blurred values
Monthly active users
blurred values

INVESTMENTS

Do you have a lead investor?
blurred values
How much have you raised in the past?
blurred values
How much of this round already committed?
blurred values
When are you aiming to close this round?
blurred values

TEAM

How much time do the founders spend on the business?
blurred values
Is there a founder with previous co-founder / c-level at startup experience?
blurred values
Is there a founder with previous Sector Experience?
blurred values
Is there a founder with previous Exit Experience?
blurred values
What percentage of company is owned by founders?
blurred values
Is there a women founder with at least 5% of the shares?
blurred values
Is there a founder with a EUR / Erasmus MC or TUDelft relation?
blurred values
Graduation year from EUR, Erasmus MC or TUDelft
blurred values

OTHER

Year founded
blurred values
Patent status
blurred values
Start your free trial today to explore this information.
‍
Start Free Trial

Premium Details

(Data is self reported)

FINANCIAL PERFORMANCE

Monthly Revenue
pre-revenue
Growth rate month over month
not growing
Monthly revenue context
Number of paying customers
0
Monthly active users
0

INVESTMENTS

Do you have a lead investor?
no
How much have you raised in the past?
1000000
How much of this round already committed?
500000
When are you aiming to close this round?
Q3 this year

TEAM

How much time do the founders spend on the business?
Is there a founder with previous co-founder / c-level at startup experience?
Yes
Is there a founder with previous Sector Experience?
No
Is there a founder with previous Exit Experience?
No
What percentage of company is owned by founders?
80-99% owned by founders
Is there a women founder with at least 5% of the shares?
No
Is there a founder with a EUR / Erasmus MC or TUDelft relation?
None of these
Graduation year from EUR, Erasmus MC or TUDelft

OTHER

Year founded
2024
Patent status
For our new drug, we have an exclusive licence agreement worldwide with University of Leiden

Basic details

Amount raising
500000
Country
Netherlands
Industry
BioTech
Website
https://www.genlumina.com
Founders
linkedin profile of founderlinkedin profile of founderlinkedin profile of founder
Last updated:
August 6, 2025

Key Achievements

  • Raised 1 million on research money in half a year. Grant for collaboration research with LUMC-hospital with their targeting peptide for colorectal cancer and our drug as payload. Six testimonials from Key Opinion Leaders stating our drug is clinical relevant for brainsurgery, dermatology, radiology and image guided surgery. Our proposition was rated 7,5 on the Bio Expert Network by 14 experts and selected for a campaign on a crowdfunding platform.

Contact this startup to discuss investments

Try it! It's free, no account needed.
This startup has indicated interest to meet with potential investors. If you are interested, please fill out the contact form below and your message will be forwarded to the startup.
Oops! Something went wrong while sending your message.

Provide anonymous feedback

Startups greatly benefit from honest feedback from investors, but rarely receive it for numerous reasons. You can anonymously provide feedback here.
Your name and email address is not shared with the startup, but needed to avoid misusage.
Oops! Something went wrong while sending your message.
Get Investor IntroductionsFind Startup InvestorsPartners & Deals
Startup Fountain
Privacy PolicyTerms & ConditionsAdd your StartupAdd InvestorInvite StartupsInvestor & Startup CategoriesSign upLoginContact me